DLC-1 gene deleted in cancers

• US 7,534,565 B2
• Filed: 11/22/2004
• Issued: 05/19/2009
• Est. Priority Date: 02/25/1998
• Status: Expired due to Fees

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Yuan, Bao-Zhu, Popescu, Nicholas, Thorgeirsson, Snorri S.
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US10/995,914
• Publication Number:
  US 20050106616A1
• Time in Patent Office: 1,639 Days
• Field of Search: 435/6, 435/91.2, 435/64, 536/23.1
• US Class Current: 435/6.14
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors

Abstract

A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.

Claims

1. A method for diagnosing a cancer in a subject, comprising detecting a decreased level of a nucleic acid molecule comprising the nucleic acid sequence set forth as SEQ ID NO:

1 in a sample from the subject, compared to a non-cancerous control sample, wherein detection of the decreased level of the nucleic acid molecule in the sample from the subject, diagnoses the cancer.

2. The method of claim 1, wherein the cancer is breast cancer.

3. The method of claim 1, wherein the cancer is liver cancer.

4. The method of claim 1, wherein the cancer is colorectal cancer.

5. The method of claim 1, wherein the cancer is prostate cancer.

6. The method of claim 1, wherein the sample is a peripheral blood, a urine, a saliva, a tissue biopsy, a surgical specimen, or an autopsy sample.

7. The method of claim 1, wherein the detection of the decreased level of the nucleic acid molecule in the sample from the subject comprises use of an amplification reaction, a hybridization reaction, or a change in electrophoretic mobility.

8. The method of claim 1, wherein the detection of the decreased level of the nucleic acid molecule in the sample from the subject comprises use of an amplification reaction, and the amplification reaction is polymerase chain reaction.

9. The method of claim 1, wherein the sample is a tissue biopsy, a surgical specimen, or an autopsy sample.

10. The method of claim 1, wherein the detection of the decreased level of the nucleic acid molecule in the sample from the subject comprises detecting decreased levels of the mRNA encoded by SEQ ID NO:

1 in a sample from the subject.

11. The method of claim 1, wherein the detection of the decreased level of the nucleic acid molecule in the sample from the subject comprises detecting a deletion of SEQ ID NO:

1 in a sample from the subject.

12. The method of claim 1 wherein the cancer is an adenocarcinoma.

13. The method of claim 12 wherein the adenocarcinoma is prostate cancer.

14. The method of claim 12 wherein the adenocarcinoma is colorectal cancer.

15. The method of claim 1 wherein the cancer is selected from liver cancer, breast cancer, colorectal cancer and prostate cancer.

16. A method for diagnosing liver cancer or breast cancer in a subject, comprising detecting a decreased level of a nucleic acid molecule comprising the nucleic acid sequence set forth as SEQ ID NO:

1 in a sample from the subject, compared to a non-cancerous control sample, wherein detection of the decreased level of the nucleic acid molecule in the sample from the subject diagnoses the cancer.